Roche presented early-stage data on its obesity injection and pill at EASD. Meanwhile, Oura enters into metabolic health ...

Roche (RHHBF) unit Genentech said Xofluza antiviral reached the main goal in a global Phase 3 trial, reducting the ...

The U.S. Food and Drug Administration on Thursday approved Roche's under-the-skin injection to treat patients with multiple ...

Roche has announced positive topline data from the Phase III CENTERSTONE clinical trial of Xofluza (baloxavir marboxil), an ...

Joplin, who misfired on the potential winning score earlier in overtime, received a long outlet pass from Redwood goalkeeper ...

The U.S. Food and Drug Administration on Thursday approved Roche's under-the-skin injection to treat patients with multiple ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

Shares in Roche dropped to a two-month low on Thursday after an experimental weight-loss pill that carries high market hopes ...

Xofluza (baloxavir marboxil), an antiviral medication, achieved its primary endpoint in the phase III CENTERSTONE ...

It’s better late than never for an FDA approval for the first subcutaneous PD-L1 inhibitor, which was doled out to Roche’s ...

Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

Deutsche Bank downgrades AstraZeneca (AZN) and Roche (RHHBY) after disappointing data for thier key pipeline assets. Read ...